Latest News and Press Releases

New york, USA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight ...

Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The global Idiopathic pulmonary fibrosis market generated US$ 2,970.69 million in 2025 and is estimated to reach US$ 6,736.49 million by 2035, growing at a...

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" has been added to ...

Boehringer launches clinical trial exploring interleukin-11’s potential to go beyond slowing IPF and restore lung function.

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE...

Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.

Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used...

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been...

"Not intended for US or UK audiences."Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the absolute change...

Transpire Bio today announced that the U.S. FDA has granted orphan drug designation (ODD) for two of its products in development.